Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $275.00. The company’s shares closed yesterday at $164.89. According to TipRanks ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (LSE:0R1B) with a Peer Perform recommendation. As of October 22, 2024, the average one-year price target for ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (SNSE:BIIB) with a Peer Perform recommendation. There are 1,775 funds or institutions reporting positions in ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...